Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecallantide continuation for acute HAE attacks
NCT00456508Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2007
- Primary completion
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of ecallantide in hereditary angioedema (HAE), sponsored by Takeda. Started Apr 2007; status: completed.
02
Drugs
ecallantide
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00456508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00456508.